New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 18, 2014
08:07 EDTMSTXMast Therapeutics reports positive data from MST-188 study
Mast Therapeutics announced new data from its randomized, placebo-controlled, nonclinical study of MST-188 in a model of chronic heart failure. MST-188 resulted in statistically significant and progressive reductions in troponin-I, at both 1 week and 2 weeks after MST-188 administration. Specifically, at 2 weeks post-administration, compared to baseline values, mean reduction troponin was 46.7% for low-dose MST-188 and 48.8% for high-dose MST-188. In contrast, troponin increased 7.7% in the control group.
News For MSTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2015
08:12 EDTMSTXMast Therapeutics to present new data supporting sickle cell disease candidate
Mast Therapeutics' lead compound, vepoloxamer, was shown in a nonclinical study to result in dose-dependent and statistically significant reductions in the adhesive properties and fragility of red blood cells from patients with sickle cell disease. The results were obtained from a microfluidics-based assessment of blood samples from 12 sickle cell patients. This data is supportive of effects the company expect to see in its Phase 3 EPIC study.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use